Mediwound Ltd
NASDAQ:MDWD

Watchlist Manager
Mediwound Ltd Logo
Mediwound Ltd
NASDAQ:MDWD
Watchlist
Price: 16.48 USD -1.67% Market Closed
Market Cap: 177.8m USD
Have any thoughts about
Mediwound Ltd?
Write Note

Mediwound Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mediwound Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Mediwound Ltd
NASDAQ:MDWD
Net Income (Common)
-$20m
CAGR 3-Years
-27%
CAGR 5-Years
N/A
CAGR 10-Years
-3%
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Net Income (Common)
-$476m
CAGR 3-Years
50%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Sol Gel Technologies Ltd
NASDAQ:SLGL
Net Income (Common)
-$9.6m
CAGR 3-Years
18%
CAGR 5-Years
20%
CAGR 10-Years
N/A
I
InterCure Ltd
TASE:INCR
Net Income (Common)
-â‚Ş62m
CAGR 3-Years
-19%
CAGR 5-Years
-37%
CAGR 10-Years
-25%
S
Seach Medical Group Ltd
TASE:SEMG
Net Income (Common)
-â‚Ş7.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-6%
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Net Income (Common)
â‚Ş6.8m
CAGR 3-Years
-9%
CAGR 5-Years
12%
CAGR 10-Years
1%
No Stocks Found

Mediwound Ltd
Glance View

Market Cap
177.8m USD
Industry
Pharmaceuticals

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

MDWD Intrinsic Value
10.47 USD
Overvaluation 36%
Intrinsic Value
Price

See Also

What is Mediwound Ltd's Net Income (Common)?
Net Income (Common)
-20m USD

Based on the financial report for Jun 30, 2024, Mediwound Ltd's Net Income (Common) amounts to -20m USD.

What is Mediwound Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-3%

Over the last year, the Net Income (Common) growth was -38%. The average annual Net Income (Common) growth rates for Mediwound Ltd have been -27% over the past three years , and -3% over the past ten years .

Back to Top